NCT05312151View on ClinicalTrials.gov

The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 10, 2022

Primary Completion Date

February 12, 2024

Study Completion Date

February 12, 2024

Conditions
Post Traumatic Stress Disorder
Interventions
DRUG

Psilocybin

Open label

Trial Locations (3)

10029

Icahn School of Medicine at Mount Sinai, New York

20850

Sunstone Therapies, Rockville

Unknown

Kings College London, Institute of Psychiatry, Psychology and Neurology, London

Sponsors

Lead Sponsor

COMPASS Pathways
All Listed Sponsors
lead

COMPASS Pathways

INDUSTRY

NCT05312151 - The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | Biotech Hunter | Biotech Hunter